Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 22 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyCompletedNCT04889118Phase 3Results posted
• Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedNCT04887870Phase 2/3Results posted
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCompletedNCT04884191Phase 2Results posted
• RegoNivo vs Standard of Care Chemotherapy in AGOCCompletedNCT04879368Phase 3Results posted
• A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisCompletedNCT04877990Phase 2Results posted
• Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)CompletedNCT04872101Phase 3Results posted
• Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand EczemaCompletedNCT04871711Phase 3Results posted
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaActive, not recruitingNCT04869137Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension StudyCompletedNCT04865289Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)Active, not recruitingNCT04857034Phase 2Results posted
• Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With MyelofibrosisTerminatedNCT04854096Phase 2Results posted
• A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)CompletedNCT04849416Phase 2Results posted
• Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerActive, not recruitingNCT04848337Phase 2Results posted
• The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic DermatitisCompletedNCT04839380Phase 2Results posted
• Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver CancerCompletedNCT04828486Phase 2Results posted
• Study for Patients Previously Treated in Avapritinib Clinical TrialsCompletedNCT04825574Phase 4Results posted
• Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic CancerCompletedNCT04820179Phase 2Results posted
• Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI TreatmentTerminatedNCT04820023Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With VitiligoCompletedNCT04818346Phase 2Results posted
• Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyTerminatedNCT04816214Phase 3Results posted
• Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT04807777Phase 2Results posted
• Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular CarcinomaCompletedNCT04798781Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)CompletedNCT04797650Phase 3Results posted
• A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy SubjectsCompletedNCT04796831Phase 1Results posted
• Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult PatientsTerminatedNCT04793399Phase 1/2Results posted
• A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia AreataCompletedNCT04784533Phase 2Results posted
• Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04783415Phase 2Results posted
• A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy ParticipantsCompletedNCT04782076Phase 1Results posted
• Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04781088Phase 2Results posted
• Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)CompletedNCT04776148Phase 3Results posted
• A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04765059Phase 3Results posted
• Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple SclerosisActive, not recruitingNCT04742400Phase 2Results posted
• Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Phase 2Results posted
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results posted
• A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingNCT04721977Phase 2Results posted
• Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal MelanomaTerminatedNCT04720417Phase 2Results posted
• Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension StudyCompletedNCT04716933Phase 3Results posted
• Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid TumorsCompletedNCT04716634Phase 2Results posted
• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)CompletedNCT04704219Phase 2Results posted
• A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid TumorsCompletedNCT04704154Phase 2Results posted
• A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanCompletedNCT04703322Phase 2Results posted
• Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsCompletedNCT04696055Phase 2Results posted
• Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationCompletedNCT04677595Phase 2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension StudyCompletedNCT04676412Phase 3Results posted
• Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I MutationCompletedNCT04666259Phase 3Results posted
• Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT04666038Phase 3Results posted
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)CompletedNCT04662710Phase 3Results posted
• Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT04657094Phase 2Results posted
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
• Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedNCT04640168Phase 3Results posted
• Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate CancerTerminatedNCT04635059Phase 2Results posted
• Brigatinib Before Brain Irradiation Trial (B3i Trial)TerminatedNCT04634110Phase 2Results posted
• A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Phase 2Results posted
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results posted
• Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TerminatedNCT04631744Phase 2Results posted
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
• Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaActive, not recruitingNCT04626791Phase 2Results posted
• Neoadjuvant Therapy for Locally Advanced Colon CancerCompletedNCT04625803Phase 2Results posted
• Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingNCT04624633Phase 2Results posted
• The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19CompletedNCT04619680Phase 4Results posted
• A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT04613518Phase 2Results posted
• Dose Escalation of Lapatinib With Paclitaxel in Ovarian CancerCompletedNCT04608409Phase 1Results posted
• Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsCompletedNCT04608344Phase 1Results posted
• A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results posted
• Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaTerminatedNCT04604132Phase 1/2Results posted
• Zanubrutinib in Patients With IgG4-Related DiseaseCompletedNCT04602598Phase 2Results posted
• Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04601857Phase 2Results posted
• Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisCompletedNCT04598269Phase 2Results posted
• A Study of Adavosertib as Treatment for Uterine Serous CarcinomaCompletedNCT04590248Phase 2Results posted
• Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal MelanomaTerminatedNCT04589832Phase 1/2Results posted
• Tofacitinib For Treatment Of Chronic PouchitisTerminatedNCT04580277Phase 2Results posted
• Open-Label Surufatinib in European Patients With NETTerminatedNCT04579679Phase 2Results posted
• Fostamatinib for Hospitalized Adults With COVID-19CompletedNCT04579393Phase 2Results posted
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT04577963Phase 1/2Results posted
• Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)CompletedNCT04562766Phase 3Results posted
• Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell MalignanciesCompletedNCT04551963Phase 1Results posted
• A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS LymphomasActive, not recruitingNCT04548648Phase 2Results posted
• Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PKCompletedNCT04546789Phase 1Results posted
• Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaTerminatedNCT04543279Phase 2Results posted
• Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in IndiaCompletedNCT04541706Phase 4Results posted
• A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are ToleratedTerminatedNCT04540874Phase 1Results posted
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedNCT04539938Phase 2Results posted
• Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With VitiligoCompletedNCT04530344Phase 3Results posted
• Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibCompletedNCT04526704Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)CompletedNCT04518995Phase 3Results posted
• PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATATerminatedNCT04517864Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGSTerminatedNCT04517253Phase 2/3Results posted
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedNCT04515394Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsCompletedNCT04511533Phase 4Results posted
• Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerTerminatedNCT04504331Phase 1Results posted
• A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaTerminatedNCT04501614Phase 1/2Results posted
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedNCT04499924Phase 2/3Results posted
• Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19TerminatedNCT04497948Phase 1Results posted
• Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line TherapyTerminatedNCT04497038Phase 1/2Results posted
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's SyndromeActive, not recruitingNCT04496960Phase 1/2Results posted
• Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaCompletedNCT04493203Phase 2Results posted
• Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis LipoidicaCompletedNCT04492618Phase 2Results posted
• A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTActive, not recruitingNCT04488822Phase 3Results posted

← Tyrosine Kinase Inhibitors overview